Awaiting development: Guidance and quality standards

Showing 11 to 20 of 343

Guidance and quality standards awaiting development
Title	Type
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339]	Technology appraisal guidance
Adalimumab for treating early Dupuytren's contracture TS ID 11870	Technology appraisal guidance
Adrenal dysfunction	Quality standard
Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care	Quality standard
Advocacy services for adults with health and social care needs	Quality standard
Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]	Technology appraisal guidance
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over TS ID 10680	Technology appraisal guidance
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments TS ID 11830	Technology appraisal guidance
Ambulatory pulmonary artery pressure monitoring devices	Diagnostics guidance
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]	Technology appraisal guidance